KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE).

Christina Schulte, Thomas Gauler, Christoph Pöttgen, Godehard Friedel, Hans-Georg Kopp, Berthold Fischer, Heinz Schmidberger, Martin Kimmich, Wilfried Budach, Sebastian Cordes, Johannes Wienker, Martin Metzenmacher, Rodrigo Hepp de Los Rios, Werner Spengler, Dirk De Ruysscher, Claus Belka, Stefan Welter, Diana Luetke-Brintrup, Maja Guberina, Filiz Oezkan, Kaid Darwiche, Martin Schuler, Karl-Heinz Jöckel, Clemens Aigner, Georgios Stamatis, Martin Stuschke, Wilfried Ernst Erich Eberhardt

Int J Cancer 156(1) 154-163

PMID39198970
PMCID-
DOI10.1002/ijc.35131
发表日期2024-08-29
入排依据:Report is a secondary analysis of a phase III trial focused on long-term toxicities and quality-of-life in survivorship, not an original report of time-to-event efficacy. No drug-containing intervention is described in this specific analysis; the intervention refers to the survivorship program structure. No OS/PFS/DFS/EFS/RFS/TTP/Kaplan-Meier/HR data are reported.
摘要

摘要

Over 40% stage-III non-small-cell lung cancer (NSCLC) patients (pts) experience 5-year survival following multimodality treatment. Nevertheless, little is known about relevant late toxicities and quality-of-life (QoL) in the further long-term follow-up. Therefore, we invited pts from our randomized phase-III trial (Eberhardt et al., Journal of Clinical Oncology 2015) after 10 years from diagnosis to participate within a structured survivorship program (SSP) including follow-up imaging, laboratory parameters, cardio-pulmonary investigations, long-term toxicity evaluations and QoL questionnaires. Of 246 pts initially accrued, 161 were considered potentially resectable following the induction therapy and were randomized (80 to arm A: definitive chemoradiation; 81 to arm B: definitive surgery; 85 not randomized for different reasons; group C). 31 from 37 pts still alive after 10 years agreed to the SSP (13 in A; 12 in B; 6 in C). Clinically relevant long-term toxicities (grade 3 and 4) were rarely observed with no signal favoring any of the randomization arms. Furthermore, available data from the global QoL analysis did not show a signal favoring any definitive locoregional approach (Mean QoL in SSP A pts: 56.41/100, B pts: 64.39/100) and no late decline in comparison to baseline and early 1-year follow-up. This is the first comprehensive SSP of very late survival follow-up reported in stage-III NSCLC treated within a randomized multimodality trial and it may serve as important baseline information for physicians and pts deciding for a locoregional treatment option.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。